Elimination of new chronic hepatitis B virus infections: Results of the Alaska immunization program

Journal of Infectious Diseases

Volumn 181, Issue 2, 2000, Pages 413-418

  Harpaz, Rafael ^a   McMahon, Brian J ^c   Margolis, Harold S ^b,e   Shapiro, Craig N ^b   Havron, Dean ^d   Carpenter, Gina ^d   Bulkow, Lisa R ^b   Wainwright, Robert B ^b  

^a CENTERS FOR DIS CONTR AND PREV   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^c INDIAN HEALTH SERVICE   (United States)

^d Bristol Bay Area Health Corporation   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; CHILD; HEPATITIS B; HUMAN; IMMUNIZATION; INFECTION CONTROL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SEROPREVALENCE; UNITED STATES;

ADOLESCENT; ADULT; ALASKA; CHILD; CHILD, PRESCHOOL; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INFANT, NEWBORN; INUITS; PREVALENCE; VACCINATION;

EID: 0034048304     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315259     Document Type: Article

References (31)

1. World Health Organization. Expanded Programme on Immunization global advisory group. Wkly Epidemiol Rec 1992;67:11-5.
2. Kane MA. Global programme for control of hepatitis B infection. Vaccine 1995;13(Suppl 1):S47-9.
3. Wainwright RB, McMahon BJ, Bulkow LR, et al. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population. JAMA 1989;261:2362-6.
4. Wainwright RB, McMahon BJ, Bulkow LR, Parkinson AJ, Harpster AP, Hadler SC. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population: preliminary results of an 8-year study. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral hepatitis and liver disease. Baltimore: Williams & Wilkins, 1991:762-6.
5. Xu ZY, Duan SC, Margolis HS, et al. Long-term efficacy of active postexposure immunization of infants for prevention of hepatitis B virus infection. J Infect Dis 1995;171:54-60.
6. Centers for Disease Control. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Morb Mortal Wkly Rep 1991;40:(RR-13)1-25.
7. Mahoney FJ, Woodruff BA, Erben JJ, et al. Effect of hepatitis B vaccination program on the prevalence of hepatitis B virus infection. J Infect Dis 1993;167:203-7.
8. Chen DS. Control of hepatitis B in Asia: mass immunization program in Taiwan. In: Hollinger FB, Lemon SM, Margolis HS, ed. Viral hepatitis and liver disease. Baltimore: Williams & Wilkins, 1991:716-9.
9. Chotard J, Inskip HM, Hall AJ, et al. The Gambia hepatitis intervention study: follow-up of a cohort of children vaccinated against hepatitis B. J Infect Dis 1992;166:764-8.
10. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997;336:1855-9.
11. Lee CL, Ko YC. Hepatitis B vaccination and hepatocellular carcinoma in Taiwan. Pediatrics 1997;99:351-3.
12. Heyward WL, Lanier AP, Bender TR, et al. Primary hepatocellular carcinoma in Alaskan natives, 1969-1979. Int J Cancer 1981;28:47-50.
13. Alward WLM, McMahon BJ, Hall DB, Heyward WL, Francis DP, Bender TR. The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. J Infect Dis 1985;151:604-9.
14. McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP. Hepatitis B related sequelae: prospective study in 1400 hepatitis B surface antigen positive Alaska native carriers. Arch Intern Med 1990;150:1051-4.
15. McMahon BJ, Bender TR, Templin DW, et al. Vasculitis in Eskimos living in an area hyperendemic for hepatitis B. JAMA 1980;244:2180-2.
16. McMahon BJ, Rhoades ER, Heyward WL, et al. A comprehensive programme to reduce the incidence of hepatitis B virus infection and its sequelae in Alaskan natives. Lancet 1987;2:1134-6.
17. Heyward WL, Bender TR, McMahon BJ, et al. The control of hepatitis B virus infection with vaccine in Yupik Eskimos: demonstration of safety, immunogenicity and efficacy under field conditions. Am J Epidemiol 1985;121:914-23.
18. McMahon BJ, Schoenberg S, Bulkow L, et al. Seroprevalence of hepatitis B viral markers in 52,000 Alaska natives. Am J Epidemiol 1993;138:544-9.
19. Alaska Area Native Health Service. Alaska native population, 1993. Anchorage, AK: Alaska Area Native Health Service, Office of Patient Care Standards, Division of Planning, Evaluation, and Health Statistics, 1993.
20. US Department of Health and Human Services. Hepatitis B program final report, 1983-1989. Washington, DC: Health and Human Services, Indian Health Service, Alaska Area Native Health Service, 1989.
21. Hadler SC, Murphy BL, Schable CA, Heyward WL, Francis DP, Kane MA. Epidemiological analysis of the significance of low positive test results on antibody to hepatitis B core antigen. J Clin Microbiol 1984;19:521-5.
22. McMahon BJ, Parkinson AJ, Helminiak C, et al. Response to hepatitis Bvaccine of persons positive for antibody to hepatitis B core antigen. Gastroenterology 1992;103:590-4.
23. Silva AE, McMahon BJ, Parkinson AJ, Sjogren MH, Hoofnagle JH, Di Bisceglie AM. Hepatitis B virus DNA in persons with isolated antibody to hepatitis B core antigen who subsequently received hepatitis B vaccine. Clin Infect Dis 1998;26:895-7.
24. Dean AG, Dean JA, Coulombier D, et al. Epi Info, version 6: a word-processing, database, and statistics program for public health on IBM-compatible microcomputers. Atlanta: CDC, 1995.
25. Margolis HS, Coleman PJ, Brown RE, Shiengold SH, Mast EE, Arevalo JA. Control of hepatitis B virus infection in the United States by routine infant vaccination: an economic analysis. JAMA 1995;274:1201-8.
26. Hall AJ, Roberston RL, Crivelli PE, et al. Cost-effectiveness of hepatitis B vaccine in The Gambia. Trans R Soc Trop Med Hyg 1993;87:333-6.
27. McMahon BJ, Alward WLM, Hall DB, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985;151:599-603.
28. Beasley RP, Hwang LY. Epidemiology of hepatocellular carcinoma. In: Vyas GN, Dienstag JL, Hoofnagle JH, eds. Viral hepatitis and liver disease. New York: Grune & Stratton, 1984:209-24.
29. Margolis HS. Prevention of acute and chronic liver disease through immunization: hepatitis B and beyond. J Infect Dis 1993;168:9-14.
30. Schreeder MT, Bender TR, McMahon BJ, et al. Prevalence of hepatitis B in selected Alaskan Eskimo villages. Am J Epidemiol 1983;118:543-9.
31. Centers for Disease Control and Prevention. Recommendations of the International Task Force for Disease Eradication. MMWR Morb Mortal Wkly Rep 1993;42(RR-16):1-38.